# Beta Glucosylceramide for Treatment of NASH

> **NCT02126306** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 23 (actual)

## Conditions studied

- Compliance Behavior

## Interventions

- **DRUG:** Beta Glucosylceramide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02126306
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02126306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02126306, "Beta Glucosylceramide for Treatment of NASH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02126306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*